Bagan L, JimŽnez Y, Leopoldo M, Rubert A, Bagan J. Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advanced stages of osteonecrosis? Med Oral Patol Oral Cir Bucal. 2017 Sep 1;22 (5):e542-7.  

 

 

doi:10.4317/medoral.22128

http://dx.doi.org/doi:10.4317/medoral.22128

 

 

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg. 2003;61:1115-7.
https://doi.org/10.1016/S0278-2391(03)00720-1

 

2. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-41.
https://doi.org/10.1016/j.tripleo.2006.06.004

 

3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67:2-12.

 

4. Allen MR, Ruggiero SL. Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2009;67:1373-7.
https://doi.org/10.1016/j.joms.2009.03.048

 

5. Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Roda R, Bagan L. Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. 19. Oral Oncol. 2012;48:753-7.
https://doi.org/10.1016/j.oraloncology.2012.02.009

 

6. Manzaneque A, Chaguaceda C, Mensa M, Bastida C, Creus-Bar— N. Use and safety of denosumab in cancer patients. Int J Clin Pharm. 2017;39:522-6.
https://doi.org/10.1007/s11096-017-0455-1

 

7. Hoefert S, Yuan A, Munz A, Grimm M, Elayouti A, Reinert S. Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). J Craniomaxillofac Surg. 2017;45:570-8.
https://doi.org/10.1016/j.jcms.2017.01.013

 

8. Vyas S, Hameed S, Murugaraj V. Denosumab-associated osteonecrosis of the jaw--a case report. 13. Dent Update. 2014;41:449-50.
https://doi.org/10.12968/denu.2014.41.5.449

 

9. Fusco V, Santini D, Armento G, Tonini G, Campisi G. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opin Drug Saf. 2016;15:925-35.
https://doi.org/10.1080/14740338.2016.1177021

 

10. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72:1938-56.
https://doi.org/10.1016/j.joms.2014.04.031

 

11. Yuan H, Niu LN, Jiao K, Pei DD, Pramanik C, Li JY, Messer R, Kumar S, Pashley DH, Tay FR. Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass. Acta Biomater. 2016;31:312-25.
https://doi.org/10.1016/j.actbio.2015.12.009

 

12. Kimachi K, Kajiya H, Nakayama S, Ikebe T, Okabe K. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:297-308.
https://doi.org/10.1007/s00210-010-0596-4

 

13. ‚ankaya M, Cizmeci Şenel F, Kadioglu Duman M, Muci E, Dayisoylu EH, Balaban F. The effects of chronic zoledronate usage on the jaw and long bones evaluated using RANKL and osteoprotegerin levels in an animal model. 17. Int J Oral Maxillofac Surg. 2013;42:1134-9.
https://doi.org/10.1016/j.ijom.2013.02.008

 

14. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws:A systematic review. Oral Dis. 2017 Jun 28. doi: 10.1111/odi.12708. [Epub ahead of print]
https://doi.org/10.1111/odi.12708

 

15. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9 Suppl 2:S66-80.
https://doi.org/10.1007/PL00004164

 

16. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032-45.
https://doi.org/10.4065/83.9.1032

 

17. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996;11:150-9.
https://doi.org/10.1002/jbmr.5650110203

 

18. Nadar RA, Margiotta N, Iafisco M, van den Beucken JJJP, Boerman OC, Leeuwenburgh SCG. Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer. Adv Healthc Mater. 2017;6.
https://doi.org/10.1002/adhm.201601119

 

19. Sandhšfer B1, Meckel M1, Delgado-L—pez JM2, Patr’cio T3, Tampieri A3, Ršsch F1, Iafisco M3. Synthesis and preliminary in vivo evaluation of well-dispersed biomimetic nanocrystalline apatites labeled with positron emission tomographic imaging agents. ACS Appl Mater Interfaces. 2015;7:10623-33.
https://doi.org/10.1021/acsami.5b02624

 

20. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006;6:307-12.
https://doi.org/10.1016/j.coph.2006.03.005

 

21. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer. 2006;13:7-26.
https://doi.org/10.1677/erc.1.01094

 

22. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.
https://doi.org/10.1056/NEJMoa0809493

 

23. Bagan J, Peydr— A, Calvo J, Leopoldo M, JimŽnez Y, Bagan L. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. Oral Dis. 2016;22:324-9.
https://doi.org/10.1111/odi.12447

 

24. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410.
https://doi.org/10.1016/j.joms.2007.08.003

 

25. Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg. 2009;67:2644-8
https://doi.org/10.1016/j.joms.2009.04.067

 

26. Bagan JV, JimŽnez Y, G—mez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol. 2008;44:1088-9.
https://doi.org/10.1016/j.oraloncology.2008.01.012

 

27. Friedlander AH, Chang TI, Hazboun RC, Garrett NR. High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia. J Oral Maxillofac Surg. 2015;73:1735-40.
https://doi.org/10.1016/j.joms.2015.03.015

 

28. Bagan J, S‡ez GT, Tormos MC, Hens E, Terol MJ, Bagan L, et al. Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws. Oral Dis. 2014;20:446-52.
https://doi.org/10.1111/odi.12150

 

29. Lee CY, Pien FD, Suzuki JB. Identification and treatment of bisphosphonate-associated actinomycotic osteonecrosis of the jaws. 2. Implant Dent. 2011;20:331-6.
https://doi.org/10.1097/ID.0b013e3182310f03

 

30. Anavi-Lev K, Anavi Y, Chaushu G, Alon DM, Gal G, Kaplan I. Bisphosphonate related osteonecrosis of the jaws: clinico-pathological investigation and histomorphometric analysis. 1. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:660-6.
https://doi.org/10.1016/j.oooo.2013.03.001

 

31. Bagan J, S‡ez GT, Tormos MC, Gavalda-Esteve C, Bagan L, Leopoldo-Rodado M, Calvo J, Camps C. Oxidative stress in bisphosphonate-related osteonecrosis of the jaws. 6. J Oral Pathol Med. 2014;43:371-7.
https://doi.org/10.1111/jop.12151

 

32. Abe T, Sato T, Kokabu S, Hori N, Shimamura Y, Sato T, et al. Zoledronic acid increases the circulating soluble RANKL level in mice, with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide. Cytokine. 2016;83:1-7.
https://doi.org/10.1016/j.cyto.2016.03.012

 

33. Koch FP, Merkel C, Ziebart T, Smeets R, Walter C, Al-Nawas B. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. 18. Clin Oral Investig. 2012 Feb;16(1):79-86.
https://doi.org/10.1007/s00784-010-0477-8

 

34. Di Nisio C, Zizzari VL, Zara S, Falconi M, Teti G, Tet G, et al. RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects. Eur J Histochem. 2015;59:2455.
https://doi.org/10.4081/ejh.2015.2455

 

35. Schiodt M, Reibel J, Oturai P, Kofod T. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:204-13.
https://doi.org/10.1016/j.oooo.2013.10.010

 

36. Mawardi H, Woo SB. Medication-related osteonecrosis of the jaws, stage 0--do we need stage 0 any more? J Oral Maxillofac Surg. 2015;73:797-7.
https://doi.org/10.1016/j.joms.2014.12.028